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ABSTRACT
Racial or ethnic minorities with leukemia who receive HLA-identical sibling hematopoietic stem cell trans-
plants (HSCTs) are reported to have worse survival when compared with whites. Characteristics of US HSCT
centers according to the proportion of ethnic minorities who undergo transplantation were compared to
explore systematic differences among centers; the association with 100-day mortality was evaluated to deter-
mine whether center factors may explain the observed discrepant survival among ethnic minorities. One
hundred sixteen US transplantation centers that performed HLA-identical sibling transplantations for leuke-
mia were analyzed. We compared physician and health care provider staffing, transplantation unit procedure
and resources, and medical center organization according to the volume procedure ratio of ethnic minorities
who underwent transplantation and also according to the ratio of Hispanics who underwent transplantation.
Centers that performed transplantation in a higher proportion of ethnic minorities were more likely to perform
fewer transplantations per year, to have fewer devoted transplant beds, to be in an urban setting, to have a lower
physician to patient volume ratio, and to follow up survivors 1 year after transplantation. Centers that
performed transplantation in a higher proportion of Hispanics were more likely to perform fewer transplan-
tations per year and to have fewer devoted transplantation beds, were less likely to perform outpatient
transplantations, were more likely to be in an urban setting, and were less likely to have posttransplantation
immunization protocols. Observed differences in center factors were not associated with 100-day mortality
after adjustment for disease severity. Our results suggest that the inferior survival reported in ethnic minorities
after HSCT may not be readily explained by center effects.
© 2005 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Numerous differences exist in health care access,
tilization, and outcomes among racial and ethnic
roups for a wide array of medical and surgical con- m
88itions in the United States. Minorities have fewer
rocedures performed for medical conditions such as
oronary artery disease, peripheral vascular disease,
nd degenerative joint disease [1-11]. Furthermore,
inorities with these conditions are often reported to
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HSCT Centers and Ethnic Minorities
Bave greater in-hospital and postprocedure morbidity
nd mortality. These inequalities have also been well
ocumented in oncology. Multiple published studies
n colorectal, genitourinary, breast, and lung cancer,
s well as on the leukemias and lymphomas, have
hown higher mortality among racial and ethnic mi-
orities [12-21]. Differences in procedure choice for
ertain conditions have also been related to race and
thnicity [15,22,23].
Disparities in outcomes among different races and
thnicities also extend to the hematopoietic stem cell
ransplantation (HSCT) setting [24-26]. HSCT is an
mportant treatment modality for different leukemias
nd lymphomas, aplastic anemia, multiple congenital
mmune deﬁciencies, and other malignancies. Re-
ently published data from the Center for Interna-
ional Blood and Marrow Transplant Research (CIB-
TR [formerly IBMTR]) showed decreased survival
ates for Hispanics with acute or chronic leukemia
hen compared with whites between 1995 and 1999
n the United States and Canada [25].
Articles on patients with malignant diseases have
dentiﬁed patient factors (socioeconomic status
SES], patient preferences, transportation, and fam-
ly support), clinical factors (stage of disease, age at
iagnosis, and comorbidities), and health care struc-
ural factors (type/status of health insurance, type of
nstitution, and geographic region) that may indi-
idually or collectively affect survival disparities
mong different races and ethnicities [27]. Addi-
ional studies have examined the effect of different
ospital and physician characteristics on morbidity
nd mortality [28-33]. Many of these studies, how-
ver, did not examine the relationship between the
acial and ethnic demographic characteristics of
heir samples and the variances among their hospi-
als’ characteristics. Such examinations of hospital
haracteristics in the context of racial and ethnic
ompositions are sparse not only in the general
edicine and surgical literature, but also in the
ncologic and HSCT settings.
We compared the physician and health provider
haracteristics, transplantation center procedure vol-
me and resources, and medical center characteristics
f HSCT centers in the United States that perform
ransplantation in a higher proportion of ethnic mi-
orities, speciﬁcally Hispanics, with characteristics of
enters that perform transplantations in a predomi-
antly white population, and we compared their 100-
ay survival while adjusting for clinical severity and
ther signiﬁcant center characteristics. We hypoth-
sized that differences in HSCT center character-
stics, according to the proportion of ethnic minor-
ties who undergo transplantation, are independent
f survival. A
B & M TETHODS
ata Collection
Data for this analysis were obtained from the CIB-
TR center characteristics annual survey. The CIB-
TR is a voluntary working group of more than 400
ransplantation centers worldwide that contribute de-
ailed data on consecutive allogeneic HSCTs to the
tatistical Center at the Health Policy Institute of the
edical College of Wisconsin (Milwaukee, WI). Ac-
ording to recent HSCT center census data, approx-
mately 40% of all allogeneic transplantations are reg-
stered with the CIBMTR, and 45% to 50% of those
re from the United States and Canada. Participating
enters are required to register all consecutive trans-
lantations, and compliance is monitored with on-site
udits. Data from patients who undergo transplanta-
ion are collected longitudinally with yearly follow-up.
he study protocol and survey questionnaire received
nstitutional review board approval.
For this analysis, only data from HSCT centers in
he United States were used. This population included
87 centers that had performed related allogeneic or
utologous transplantations between 1998 and 2000
or hematologic malignancies: acute lymphoblastic
eukemia, acute myeloblastic leukemia, chronic my-
logenous leukemia, Hodgkin lymphoma, and non-
odgkin lymphoma. All centers received a detailed
nquiry regarding multiple characteristics of their
edical organizations and providers. An itemized list-
ng of these variables is presented in the “Analysis” por-
ion of this section. Of the 187 centers surveyed, 163
87%) responded, 6 (3%) refused to participate, and 18
10%) were excluded because those transplantation
eams no longer contribute data to the CIBMTR. Of the
63 transplantation centers that completed the inquiry,
13 (69%) performed HLA-identical sibling HSCT.
n additional 3 non-CIBMTR US HSCT centers
articipated in the survey. Thus, a total of 116 US
SCT centers were included in the descriptive part of
he study.
tudy Population
The patient’s ethnicity was abstracted from data
ubmitted by the transplantation center to the CIB-
TR. Patients considered to be ethnic minorities in
he database are reported to be “African American,”
Caribbean black,” “South or Central American
lack,” or “black unspeciﬁed” descent; “Caribbean His-
anic,” “Mexican/Southwestern United States His-
anic,” “South or Central American Hispanic,” or “His-
anic unspeciﬁed” descent; “Asian Indian,” “Filipino,”
Hawaiian/Polynesian,” “Japanese,” “Korean,” “North-
rn Chinese,” “Southeast Asian/Southern Chinese,” or
Oriental unspeciﬁed” descent; and “Native Ameri-
an”, “American Indian,” or “Native Alaskan/Eskimo/
leut.” We limited the analysis to centers performing
989
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9llogeneic transplantation because preliminary analy-
is (data not shown) of survival outcomes after autol-
gous transplantation for hematologic malignancies
y ethnicity did not show statistically signiﬁcant dif-
erences after controlling for patient-, disease-, and
ransplant-related prognostic factors.
The transplantation centers included in this study
ere divided into 2 groups for 2 separate analyses
ased on minority procedure volume. We deﬁned
rocedure volume as the proportion of racial or ethnic
inorities who undergo transplantation annually per
enter, regardless of diagnosis. We compared centers
hat perform transplantation for a higher procedure
olume proportion of ethnic minorities (centers where
20% of all HSCTs are in ethnic minorities) with
enters that perform transplantation in a relatively
ower proportion of ethnic minorities. The 20% cut-
ff was based on the 2000 US national census ﬁgure of
4.9% ethnic minorities [34]. Thereafter, we com-
ared centers by the procedure volume proportion of
ispanics who undergo transplantation. For this anal-
sis, teams performing 10% of HSCTs for Hispan-
cs were considered as higher-procedure-volume cen-
ers. This approximates the 2000 US census data,
hich indicate that Hispanics comprise 12.5% of the
otal US population [34]. A separate analysis was per-
ormed among Hispanics because our previous work
dentiﬁed Hispanics to be the group at greatest risk for
arly mortality after HSCT when compared to other
thnicities after controlling for prognostic factors [25].
nalysis
The 2 test for categorical variables and the Wil-
oxon rank-sum 2-sample test for continuous variables
ere used to compare groups in 3 areas: (1) physician
nd health care provider characteristics, (2) transplan-
ation unit procedure activities and resources, and (3)
edical center organization. The following HSCT
hysician and health care provider characteristics were
xamined: (1) total number of physicians per center,
2) ratio of physicians per total number of transplan-
ations per year, (3) academic appointments of physi-
ians, (4) proportion of physicians with peer-reviewed
rants, (5) proportion of physicians involved in labo-
atory research, (6) presence of medical trainees (med-
cal students, training residents, and fellows), and (7)
verage daily nurse-patient ratio in the transplantation
nit.
The following transplantation unit activities and
esources were examined:
. HSCT activity, including the total number and type
(autologous, related, unrelated, cord blood, nonmyeloa-
blative, and outpatient) of transplantations per year and
years of experience performing HSCT.
. Infrastructure, hospital bed capacity, number of beds
devoted to HSCT patients, presence of laminar ﬂow and t
90high-efﬁciency particulate air–ﬁltered rooms, ability to
manage critically ill patients on the transplantation
unit, presence of an HSCT unit pharmacist, use of
computerized order entry and electronic medical record
keeping, and presence of an on-site stem cell–processing
laboratory.
. Research activity, including the percentage of patients
enrolled in institutional review board–approved clinical
protocols and the number of full-time clinical research
coordinators.
. Support services, including the presence of an HSCT-
devoted psychologist/psychiatrist, use of routine psycho-
logical screening, and an initial contact provider for
emergency or after-ofﬁce calls.
. Follow-up procedures, including the presence of and
frequency of systematic posttransplantation follow-up,
the presence of a long-term follow-up program, the
frequency of routine follow-up within the ﬁrst year and
beyond the ﬁrst year after transplantation, the presence
of a formal immunization protocol, and the presence of
a formal protocol for screening for posttransplantation
complications.
The following medical center characteristics were
xamined: geographic location, afﬁliation with a med-
cal school, Center for Excellence designation, Na-
ional Cancer Institute cancer center designation, and
ccreditation by the Foundation for the Accreditation
f Cellular Therapy.
Center characteristics were entered in a stepwise
ultivariate analysis by using Cox proportional haz-
rds regression to evaluate their association with 100-
ay mortality (100-day mortality is deﬁned as death
rom any cause within the ﬁrst 100 days after HSCT).
e chose 100 days because our previous study showed
hat center effects exert their inﬂuence on survival
utcome within this time frame [35]. A main-effect
erm to designate the proportion of ethnic minorities
ho undergo transplantation (20% ethnic minori-
ies versus 20% ethnic minorities and 10% His-
anics versus 10% Hispanics) was held in all model
uilding.
Another factor we evaluated and adjusted for in
he model building was the clinical severity of the
atients treated at each center. We computed a clin-
cal severity score based on the case mix of the cohort,
sing the patient’s age, disease, and disease stage.
hese 3 covariates were the only patient and disease
haracteristics associated with survival in the model
uilding. A detailed description of this procedure is
iscussed in our previous study [35]. The clinical se-
erity score was used in the ﬁnal models for center
ffects to adjust for the severity of illness of the pa-
ients who underwent transplantation at the centers.
he multivariate analysis was limited to 88 transplan-
ation centers (1426 patients) with eligible acute and
hronic leukemia patients who underwent HLA-iden-
ical sibling transplantation. Because this was an ex-
Table 1. Characteristics of Centers Performing Allogeneic Transplantation in the United States According to the Proportion of Racial/Ethnic Minorities
Variable Total >20% Minorities >20% Minorities P Value <10% Hispanics >10% Hispanics P Value
No. centers 116 62 (53) 54 (47) 88 (76) 28 (24)
Procedure volume
Total no. transplantations/year, median (range) 56 (8-458) 66 (2-245) 40 (4-458) .01 62 (2-245) 36 (4-458) .02
<30 32 (28) 12 (19) 20 (37) .07 20 (23) 12 (43) .14
31-60 29 (25) 14 (23) 15 (28) 22 (25) 7 (25)
61-99 30 (26) 19 (31) 11 (20) 24 (27) 6 (21)
>100 25 (21) 17 (27) 8 (15) 22 (25) 3 (11)
Total no. ethnic minorities or Hispanics/year, median (range) 26 (0-280) 21 (1-105) 36 (6-280) <.001 3 (0-56) 30 (4-151) .007
Total no. allogeneic transplantations/year, median (range) 18 (3-206) 24 (2-150) 14 (3-206) .17 20 (3-150) 15 (3-206) .19
<8 30 (26) 15 (24) 15 (28) .31 21 (24) 9 (32) .64
8-20 31 (27) 13 (21) 18 (33) 23 (26) 8 (29)
21-40 29 (25) 17 (27.5) 12 (22) 22 (25) 7 (25)
>40 26 (22) 17 (27.5) 9 (17) 22 (25) 4 (14)
Type of transplantations performed
Related 116 (100) 62 (100) 54 (100) NA 88 (100) 28 (100) NA
Unrelated 77 (66) 42 (68) 35 (65) .74 58 (66) 19 (68) .84
Cord blood 49 (42) 22 (35) 27 (50) .11 31 (35) 18 (64) .01
Nonmyeloablative 78 (67) 43 (69) 35 (65) .60 60 (68) 18 (64) .70
Outpatient 56 (48) 35 (56) 21 (39) .06 49 (56) 7 (25) .005
No. of different types of transplantations performed
2 11 (9) 3 (5) 8 (15) .09 7 (8) 4 (14) .33
3 24 (21) 17 (27) 7 (13) 21 (24) 3 (11)
4 29 (25) 14 (23) 15 (28) 20 (23) 9 (32)
5 32 (28) 15 (24) 17 (31) 23 (26) 9 (32)
6 20 (17) 13 (21) 7 (13) 17 (19) 3 (11)
Center Experience
Years of experience, median (range) 11 (1-33) 11 (1-33) 11 (1-28) .97 11 (1-33) 11 (1-28) .84
<5 18 (15) 11 (18) 7 (13) .55 15 (17) 3 (10.33) .36
5-10 37 (32) 18 (29) 19 (35) 27 (31) 10 (35.33)
11-15 30 (26) 14 (22) 16 (30) 20 (23) 10 (35.33)
>15 31 (27) 19 (31) 12 (22) 26 (30) 5 (18)
Data are n (%) unless otherwise noted.
NA indicates not applicable.
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9loratory study, a P value of.05 was considered to be
tatistically signiﬁcant for all of the center characteristics
ested in the multivariate model. Analyses were per-
ormed with SAS Version 8.0 (SAS Institute, Cary, NC).
ESULTS
llogeneic Transplantation Center Profile
ccording to the Proportion of Minorities
A total of 116 US transplantation centers partici-
ated in the study. Sixty-two (53%) centers performed
ransplantations in fewer than 20% ethnic minorities
nd were classiﬁed as part of the low-percentage mi-
ority cohort. Fifty-four (47%) centers performed
ransplantations in at least 20% minorities and were
lassiﬁed as the high-percentage minority cohort.
Tables 1 to 4, columns 3 and 4, show the compar-
sons between the high- versus low-percentage minor-
ty cohort centers. The high-percentage minority co-
ort centers performed signiﬁcantly fewer total
ransplantations per year (median, 40 versus 66; P 
01) and fewer allogeneic transplantations per year
median, 14 versus 24; P  .17). They had a lower
hysician-to-patient ratio (median, 1:13 versus 1:16;
 .03), were more likely to be located in urban areas
93% versus 73%; P .01), had fewer devoted HSCT
eds (median, 10 versus 13; P  .05), and were more
ikely to have a formal long-term follow-up program
83% versus 66%; P  .03).
llogeneic HSCT Center Profile According to the
roportion of Hispanics
Twenty-eight (24%) centers performed at least
0% of their annual transplantations on patients of
ispanic ethnicity and were grouped in the high-
ercentage Hispanic cohort. Eighty-eight (76%)
enters performed fewer than 10% of their trans-
lantations on Hispanics and were classiﬁed as the
ow-percentage Hispanic cohort. All centers with a
igh Hispanic percentage also had a high minority
ercentage. Comparison of the center characteristics
etween these 2 cohorts is shown in Tables 1 to 4,
olumns 6 and 7.
The high- and low-percentage Hispanic HSCT
enters did not differ signiﬁcantly on any of the phy-
ician and health care provider characteristics, includ-
ng the number of physicians per total transplantation
atients per year (Table 2). However, high-percentage
ispanic HSCT centers, like the high-percentage mi-
ority centers, performed fewer transplantations per
ear (median, 36 versus 62; P  .02), had signiﬁcantly
ewer devoted HSCT patient beds (median, 7 versus
2; P  .001), and were more likely to be in urban
reas (96% versus 77%; P  .02). In contradistinction
o the ﬁndings of the high-percentage minority cen-
ers, the high-percentage Hispanic HSCT centers
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Table 3. Transplantation Unit Proﬁles and Resources
Variable Total
<20%
Minorities
>20%
Minorities P Value
<10%
Hispanics
>10%
Hispanics P Value
Hospital bed capacity
<99 12 (10) 9 (15) 3 (5) .003 10 (11) 2 (7) .001
100-299 18 (16) 4 (6) 14 (26) 7 (8) 11 (39)
300-499 29 (25) 21 (34) 8 (15) 23 (26) 6 (22)
>500 57 (49) 28 (45) 29 (54) 48 (55) 9 (32)
Have devoted beds for BMT patients 114 (98) 60 (97) 54 (100) .18 86 (98) 28 (100) .42
Median (range) 11 (3-70) 13 (4-36) 10 (3-70) .05 12 (4-36) 7 (3-70) .001
Laminar air-flow rooms
None 75 (65) 42 (68) 33 (61) .56 61 (69) 14 (50) .15
Some 21 (18) 9 (14) 12 (22) 13 (15) 8 (29)
All 20 (17) 11 (18) 9 (17) 14 (16) 6 (21)
HEPA-filtered rooms
None 7 (6) 5 (8) 2 (4) .60 5 (6) 2 (7) .42
Some 20 (17) 10 (16) 10 (18) 13 (15) 7 (25)
All 89 (77) 47 (76) 42 (78) 70 (79) 19 (68)
% of patients enrolled in IRB-approved clinical protocols
<25% 21 (18) 9 (15) 12 (22) .20 17 (19) 4 (14) .80
26-50% 30 (26) 20 (32) 10 (19) 23 (26) 7 (25)
>50% 65 (56) 33 (53) 32 (59) 48 (55) 17 (61)
Full-time clinical research coordinators
None or 1 61 (53) 27 (44) 34 (63) .11 43 (49) 18 (64) .36
2 26 (22) 17 (27) 9 (17) 21 (24) 5 (18)
>3 29 (25) 18 (29) 11 (20) 24 (27) 5 (18)
Units able to manage critically ill patients 33 (28) 22 (35) 11 (20) .07 29 (33) 4 (14) .06
Computerized order entry 83 (72) 43 (69) 40 (74) .57 63 (72) 20 (71) .99
Electronic medical record keeping 66 (57) 35 (56) 31 (57) .92 50 (57) 16 (57) .98
On-site stem cell–processing laboratory 106 (91) 54 (87) 52 (96) .08 81 (92) 25 (89) .65
Unit pharmacist present 108 (93) 56 (90) 52 (96) .20 81 (92) 27 (96) .43
NCI-designated cancer center 82 (71) 44 (71) 38 (70) .94 65 (74) 17 (61) .18
Devoted psychologist/psychiatrist present 73 (63) 37 (60) 36 (67) .44 54 (61) 19 (68) .54
Routine psychological screening 102 (88) 52 (84) 50 (93) .15 76 (86) 26 (93) .36
Initial contact person
Nurse/nurse practitioner/physician assistant 30 (26) 18 (29) 12 (22) .47 26 (29) 4 (14) .22
Resident 37 (32) 21 (34) 16 (30) 28 (32) 9 (32)
Hematology/oncology or BMT attending/fellows 49 (42) 23 (37) 26 (48) 34 (39) 15 (54)
Systematic follow-up of patients 99 (85) 53 (85) 46 (85) .40 75 (85) 24 (86) .07
Every 6 mo 30 (26) 16 (26) 14 (26) 19 (21) 11 (39)
Every year 48 (41) 29 (47) 19 (35) 42 (48) 6 (22)
Every other year 21 (18) 8 (13) 13 (24) 14 (16) 7 (25)
No systematic follow-up 17 (15) 9 (14) 8 (15) 13 (15) 4 (14)
Programs have formal long-term follow-up program 86 (74) 41 (66) 45 (83) .03 63 (72) 23 (82) .26
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994erformed a smaller proportion of transplantations in
he outpatient setting (25% versus 56%; P  .005),
nd were less likely to have a formal protocol to
dentify deﬁciencies and increase compliance in pa-
ient immunization proﬁles after transplantation (61%
ersus 83%; P  .01). The 2 cohorts did not vary
igniﬁcantly for other HSCT unit and medical center
haracteristics (Tables 3 and 4).
utcome Analysis
Table 5 shows the multivariate analysis evaluating
he association between the proportion of racial/
thnic minorities who undergo transplantation and
00-day mortality after adjustment for clinical severity
nd other signiﬁcant center factors. The relative risk
f death within 100 days after transplantation among
enters that perform transplantation in 20% ethnic
inorities when compared with centers that perform
ransplantation in 20% ethnic minorities is 0.99
95% conﬁdence interval, 0.75-1.31; P  .95). In a
eparate model, the relative risk of death within 100
ays among centers that perform transplantation in
10% Hispanics when compared with centers that
erform transplantation in 10% ethnic minorities is
.99 (95% conﬁdence interval, 0.72-1.36; P  .95).
sing different cutoff values for the proportions of
thnic minorities and Hispanics who undergo trans-
lantation at each center showed essentially the same
ndings. We also performed the multivariate analysis
y using the actual number of ethnic minorities or
ispanics who undergo transplantation instead of the
roportion of ethnic minorities or Hispanics who un-
ergo transplantation per year and found the same
esults. We also evaluated clinical severity according
o the proportion of ethnic minorities who undergo
ransplantation and did not ﬁnd any statistically sig-
iﬁcant differences.
ISCUSSION
Our analyses showed that transplantation centers
ith a high proportion (20%) of racial and ethnic
inorities or a high proportion of Hispanic patients
10%) are different from centers that perform fewer
inority transplantations, but these differences are
ot associated with adverse outcomes. Speciﬁcally,
enters that perform a high number of minority pro-
edures are more likely to perform fewer total trans-
lantations per year, to have a lower ratio of physi-
ians to total number of transplant recipients per year,
o have fewer hospital beds devoted to HSCT recip-
ents, to have a formal long-term follow-up program,
nd to be located in an urban setting when compared
ith centers that perform a smaller proportion of
acial and ethnic minorities (20%). Similarly, trans-
plantation centers whose total annual transplantationTa Fr
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Bolumes were at least 10% Hispanic ethnicity were
ore likely to perform fewer total transplantations per
ear, have fewer hospital beds devoted to HSCT re-
ipients, and be located in urban areas. In addition,
enters that performed transplantation in a higher
ercentage of Hispanic patients were less likely to
erform outpatient HSCT or to have a formal post-
ransplantation immunization protocol in place. How-
ver, despite these differences, 100-day mortality did
ot signiﬁcantly differ according to the proportion of
thnic minorities undergoing transplantation after
ontrolling for clinical severity. This suggests that the
urvival differences among ethnic minorities reported
n previous studies may not be explained by differ-
nces in center characteristics. Similarly, there were
o differences in the clinical severity of disease in
able 5. Multivariate Analysis for 100-Day Survival*
Variable
roportion of minorities (or minority procedure volume)†
Patients in centers performing <20% ethnic minorities
Patients in center performing >20% ethnic minorities
roportion of Hispanics (or Hispanic procedure volume)‡
Patients in centers performing <10% Hispanics
Patients in centers performing >10% Hispanics
ignificant factors
Clinical severity score
Less than median
Greater than or equal to median
Physician case load
<20 patients/year
>20 patients/year
Initial contact for after-office or emergency calls
Non physicians
Physicians
Medical school affiliation
Non–medical schools
Medical schools with students and residents
Medical schools with fellows
Medical school students, residents, and fellows
The unit of analysis in the model is the actual patient number.
Model with proportion of ethnic minorities forced in the model w
able 4. Medical Center Characteristics
Variable Total
<20%
Minorities
ocation
Urban 95 (82) 45 (73)
Suburban/rural 21 (18) 17 (27)
edical school affiliations 91 (78) 50 (81)
enter for Excellence designation 77 (66) 40 (34)
ACT accreditation
No 23 (20) 8 (13)
Yes, pending 33 (28) 17 (27)
Yes 60 (52) 37 (60)
ACT indicates Foundation for the Accreditation of Cellular Ther
ata are n (%).Model with proportion of Hispanics forced in the model with other sign
B & M Transplantation patients according to the proportion
f ethnic minorities (data not shown).
We previously reported an increased risk of death
mong Hispanics after HLA-identical sibling HSCT
or leukemia after adjustment for disease severity [25].
lthough we suggested several hypotheses to explain
hese disparate outcomes, including social, cultural, and
conomic factors, we were unable to investigate these
ypotheses with the available retrospective data. Center
ffects can illustrate on a macro level that systematic
ifferences in health care delivery can affect outcomes.
ur previous study on center effects showed that there
re center characteristics associated with 100-day mor-
ality after HLA-identical sibling transplantation [34].
his study examined whether center effects might
xplain discrepant outcomes among ethnic minorities
n
Relative Risk
(95% Confidence Interval) P Value
805 1.00
621 0.99 (0.75-1.31) .95
1068 1.00
358 0.99 (0.72-1.36) .95
905 1.00
521 3.19 (2.45-4.15) <.001
762 1.00
664 0.66 (0.50-0.87) .003
402 1.00
1024 0.70 (0.51-0.96) .03
283 1.00
57 2.34 (1.14-4.79) .02
390 1.42 (0.91-2.23) .12
696 1.43 (0.98-2.10) .06
er signiﬁcant factors.
20%
orities P Value
<10%
Hispanics
>10%
Hispanics P Value
(93) .01 68 (77) 27 (96) .02
(7) 20 (23) 1 (4)
(76) .54 68 (77) 23 (82) .58
(69) .65 59 (67) 18 (64) .79
(28) .09 14 (16) 9 (32) .17
(30) 26 (29.5) 7 (25)
(42) 48 (54.5) 12 (43)ith oth>
Min
50
4
41
37
15
16
23
apy.iﬁcant factors.
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9fter HSCT. Our inability to document a relationship
etween center effects and outcomes according to the
roportion of ethnic minorities who undergo trans-
lantation suggests the following hypotheses: (1) our
easures of center characteristics did not capture the
actors that inﬂuence patient survival; (2) systematic
ifferences in health care delivery factors according to
he proportion of minorities is not a predictor of
ortality; (3) ethnicity is a surrogate for some biolog-
cal entity that predicts outcomes after HSCT; (4)
thnicity is a complex biological, social, economic,
sychological, and cultural concept that has direct
ffects on outcomes and exerts effects not on health
are delivery factors but rather on some biological,
nd possibly clinical, factors; (5) ethnicity interacts
ith social, economic, and cultural factors to cause
ome intermediate processes, possibly behaviorally
ediated, and these intermediate processes lead to
isparate outcomes; or (6) a combination of these. We
re currently exploring these various hypotheses by
sing prospectively collected data.
Additionally, in our previous studies, we failed to
how a center effect in the autologous HSCT setting
nd likewise failed to show differences in survival
utcomes across racial and ethnic differences. We
ypothesized that survival after autologous transplan-
ation was both more likely and more dependent on
isease characteristics than survival after allogeneic
ransplantation. This may explain why we were not
ble to document a race/ethnicity effect in autologous
ransplantation. In contrast, allogeneic transplantation
s associated with a higher risk of treatment-related
ortality and is perhaps inﬂuenced more by race/
thnicity, either through a biological (variation in
harmacologic sensitivities, drug metabolism, HLA
istribution, tumor-suppressor genes, and proto-
ncogenes) or a sociocultural (health care access and
elivery, socioeconomic, cultural, and psychological)
echanism.
Systematic differences in high- and low-volume
inority procedure centers could be reinforced by
everal inﬂuences. Data from the CIBMTR suggest
hat the number of transplantations performed in
lacks and Hispanics has increased over the last de-
ade [25]. At the same time, according to the 2000 US
ensus data, a larger proportion of black and Hispanic
opulations reside in urban communities [34,36,37]
nd have the highest poverty rates among racial and
thnic groups, at 24% and 23%, respectively [34,36,37].
or example, 32% of Hispanics had no insurance cov-
rage in 2002 [38]. Existing literature has shown that
eople of lower SES are more likely to have diseases
hat are untreated, combined with a related decrease
n availability and use of health care resources [39,40].
ultiple factors can inﬂuence entry into and contin-
ance of care for people of lower SES, including
atient access to transportation, level of education,
96atient knowledge and health beliefs, patient and phy-
ician relationship, and an inability to access care sec-
ndary to competing work and family responsibilities
38]. It seems quite reasonable, therefore, that trans-
lantation centers that serve populations at a higher
isk of decreased compliance have initiated formal
ong-term follow-up programs when compliance with
herapy and frequent re-evaluation are essential to
urvival outcomes. Although we did not measure the
roportion of patients from local rather than distant
eferrals, it is also likely that centers with higher mi-
ority populations retain responsibility for long-term
ost-HSCT care.
Our study has several limitations. A considerable
umber of centers were excluded in the outcomes
nalysis component of our study in our attempt to
etect center effects by using a homogenous sample of
dult leukemia patients. This is essential to truly ap-
reciate the contribution of center effects on outcome.
dditionally, we were unable to evaluate survival by
he geographic location of centers, because the geo-
raphic location of centers was signiﬁcantly correlated
ith the proportion of ethnic minorities. The issue of
enter differences by geographic location is a far more
omplicated issue that needs separate analyses and
ould require a closer look at practice variations. The
ack of standard quality-assurance measures in HSCT
lso prevents further examination of practice varia-
ions in HSCT.
In summary, centers that perform transplantation
n high versus low percentages of minority patients,
peciﬁcally Hispanics, differ when characteristics that
eﬁne the individual centers are examined. Differ-
nces in center characteristics according to the pro-
ortion of ethnic minorities who undergo transplan-
ation (low and high procedure volume) were not
ssociated with 100-day mortality after HLA sibling
ransplantation for leukemia after controlling for clin-
cal severity. Future research should focus on disen-
angling biological, economic, social, and cultural
haracteristics of patients in the light of ethnicity to
xplain disparate outcomes after allogeneic HSCT.
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